- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07280754
Bewertung der 25(OH)D3- und LL-37-Spiegel in der periimplantären Sulcusflüssigkeit
Evaluation von 25(OH)D3- und LL-37-Spiegeln in der periimplantären Sulkusflüssigkeit bei periimplantären Erkrankungen
Despite technological advances that have significantly improved dental implant osseointegration and survival rates, biological complications such as peri-implantitis and peri-implant mucositis are common around the implant. The active form of vitamin D, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), can be induced by the expression of leucine-lysine-37 (LL-37), a human antimicrobial peptide in the cathelicidin family. Studies have shown that 1,25(OH)2D3 and its precursor, 25(OH)D3, significantly reduce inflammation by suppressing the release of receptor activator nuclear factor kappa b ligand (RANKL), tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1, and IL-6, and by preventing alveolar bone loss. To date, many cytokines have been investigated in peri-implant sulcus fluid (PIOS). The lack of a direct study investigating vitamin D and LL-37 levels in PIOS constitutes the unique value of this project. This study aims to compare LL-37 and 25(OH)D3 levels in PIOS and examine their correlation with markers such as IL-6, IL-10, and MMP-8, as well as clinical parameters. Volunteers aged 18-65 who have received dental implants at the Recep Tayyip Erdoğan University Faculty of Dentistry and have been using their implant-supported prosthesis for at least one year and who have been informed about this study will be included in the study. The groups will be formed as peri-implant health, peri-implant mucositis, and peri-implantitis. The implants of the patients included in the study will be evaluated for probed pocket depth (PPD), clinical attachment level (CAL), suppuration (S), modified gingival index (mGI), plaque index (mPI), bleeding index (mBI), keratinized gingival amount, and attached gingival amount. PIOS and serum samples will be obtained from patients, and their relationship to periodontal status and each other will be statistically evaluated.
This project may help discover new biomarkers that can be used in the early diagnosis of peri-implantar diseases. This study could contribute to earlier treatment, lower patient costs, and even the development of new treatment plans for these diseases.
Studienübersicht
Status
Bedingungen
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienorte
-
-
Islampasa Street
-
Rize, Islampasa Street, Türkei (türkiye), 53020
- Rekrutierung
- Recep Tayyip Erdoğan University
-
Kontakt:
- MELEK BEDER
- Telefonnummer: 05347615837
- E-Mail: melek.beder@erdogan.edu.tr
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
The G*Power analysis performed to determine the number of samples to be included in the study determined that a total of 72 samples/implants should be included, with a minimum of 24 in each group, when the power of the test was taken as 0.85, the effect size as 0.4, and the Type-1 error (α) as 0.05.
Beschreibung
Inclusion Criteria:
- Being between the ages of 18-65,
- Having dental implants and using implant-supported prostheses for at least one year,
- Not having used systemic and/or topical antibiotics/anti-inflammatory drugs or mouthwashes in the last three months,
- Not having received periodontal/peri-implant treatment in the last six months.
Exclusion Criteria:
- Having a systemic disease or condition that affects peri-implant status,
- Having a metabolic bone disease,
- Bruxism,
- Being pregnant or lactating,
- Having received periodontal/peri-implant treatment within the last 6 months,
- Smoking and alcohol use,
- Taking vitamin D supplements.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
healthy group
Criteria such as absence of clinical signs of inflammation in the tissues, absence of bleeding on probing, PPD ≤5.0 mm, and absence of bone loss greater than 2 mm after initial healing will be sought. |
|
peri-implant mucositis
Criteria such as clinical signs of inflammation (erythema, swelling, suppuration) in the tissues, bleeding on probing, and an PPD of 5.0 mm will be sought. At the time of implant placement, the height of the surrounding soft tissue influences the initial probing depth. |
|
periimplantitis
Bleeding, inflammation, redness, edema, suppuration, and in addition to these, bone loss >5 mm and radiographically observed in PPD are observed in the tissues. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Probing pocket depth (PPD)
Zeitfenster: baseline
|
The distance from the gingival margin to the pocket base around the implants was measured in mm using a periodontal probe, at six locations for each implant. The average value will be determined for each implant circumference. |
baseline
|
|
clinical attachment level (CAL)
Zeitfenster: baseline
|
Similar to the PPD measurement, this will be done by determining the distance between the pocket base and the implant neck. |
baseline
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
25-Hydroxy Vitamin D3 ((25(OH)D3))
Zeitfenster: baseline
|
25(OH)D3 levels in PIOS samples will be analyzed by ELISA or CMIA methods. |
baseline
|
|
leucine leucine-37 (LL-37)
Zeitfenster: baseline
|
LL-37 levels in PIOS samples will be evaluated by ELISA method. |
baseline
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- Recep Tayyip Erdogan U
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .